Targeting GRPR in urological cancers - From basic research to clinical application

Nature Reviews Urology

Volumn 10, Issue 4, 2013, Pages 235-244

  Mansi, Rosalba ^a   Fleischmann, Achim ^b   Mäcke, Helmut R ^a   Reubi, Jean C ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BOMBESIN; BOMBESIN ANTAGONIST; COPPER 64; FLUORINE 18; GALLIUM 68; GASTRIN RELEASING PEPTIDE RECEPTOR; INDIUM 111; LUTETIUM 177; NEUROMEDIN C; TECHNETIUM 99M; TETRAXETAN;

AMINO ACID SEQUENCE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER GRADING; CANCER RADIOTHERAPY; CANCER THERAPY; COLON CANCER; DOUBLE STRANDED DNA BREAK; ENDOMETRIUM CANCER; GASTRINOMA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; METASTASIS; NONHUMAN; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION DOSE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; URINARY TRACT CANCER;

ANIMALS; BIOMEDICAL RESEARCH; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RECEPTORS, BOMBESIN; UROLOGIC NEOPLASMS;

EID: 84876138141     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2013.42     Document Type: Review

References (105)

1. Mottet, N. et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 59, 572-583 (2011).
2. Bastian, P. J. et al. High-risk prostate cancer: From definition to contemporary management. Eur. Urol. 61, 1096-1106 (2012).
3. Heidenreich, A. et al. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur. Urol. 59, 61-71 (2011).
4. Yap, T. A., Zivi, A., Omlin, A. & de Bono, J. S. The changing therapeutic landscape of castration-resistant prostate cancer. Nat. Rev. Clin. Oncol. 8, 597-610 (2011).
5. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29 (2012).
6. Huggins, C., Stevens, R. E. Jr & Hodges, C. V. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43, 209-223 (1941).
7. Feldman, B. J. & Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34-45 (2001).
8. Corcoran, N. M. & Gleave, M. E. Targeted therapy in prostate cancer. Histopathology 60, 216-231 (2012).
9. Reubi, J. C. & Maecke, H. R. Peptide-based probes for cancer imaging. J. Nucl. Med. 49, 1735-1738 (2008).
10. Imhof, A. et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J. Clin. Oncol. 29, 2416-2423 (2011).
11. Kwekkeboom, D. J. et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: Toxicity, efficacy, and survival. J. Clin. Oncol. 26, 2124-2130 (2008).
12. Ambrosini, V., Fani, M., Fanti, S., Forrer, F. & Maecke, H. R. Radiopeptide imaging and therapy in Europe. J. Nucl. Med. 52 (Suppl. 2), 42S- 55S (2011).
13. Anastasi, A., Erspamer, V. & Bucci, M. Isolation and structure of bombesin and alytesin, 2 analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia 27, 166-167 (1971).
14. Erspamer, V., Erpamer, G. F. & Inselvini, M. Some pharmacological actions of alytesin and bombesin. J. Pharm. Pharmacol. 22, 875-876 (1970).
15. Erspamer, V. Discovery, isolation, and characterization of bombesin-like peptides. Ann. NY Acad. Sci. 547, 3-9 (1988).
16. Jensen, R. T., Battey, J. F., Spindel, E. R. & Benya, R. V. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: Nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol. Rev. 60, 1-42 (2008).
17. McDonald, T. J. et al. Characterization of a gastrin releasing peptide from porcine non-antral gastric tissue. Biochem. Biophys. Res. Commun. 90, 227-233 (1979).
18. Minamino, N., Kangawa, K. & Matsuo, H. Neuromedin C: A bombesin-like peptide identified in porcine spinal cord. Biochem. Biophys. Res. Commun. 119, 14-20 (1984).
19. Jensen, R. T. & Moody, T. W. in Handbook of Biologically Active Peptides (ed. Kastin, A. J.) 429-434 (Elsevier, Amsterdam, 2006).
20. Gorbulev, V., Akhundova, A., Buchner, H. & Fahrenholz, F. Molecular cloning of a new bombesin receptor subtype expressed in uterus during pregnancy. Eur. J. Biochem. 208, 405-410 (1992).
21. Fathi, Z. et al. BRS 3: A novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J. Biol. Chem. 268, 5979-5984 (1993).
22. Fleischmann, A., Waser, B. & Reubi, J. C. High expression of gastrin-releasing peptide receptors in the vascular bed of urinary tract cancers: Promising candidates for vascular targeting applications. Endocr. Relat. Cancer 16, 623-633 (2009).
23. Reubi, J C., Wenger, S., Schmuckli-Maurer, J., Schaer, J. C. & Gugger, M. Bombesin receptor subtypes in human cancers: Detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin. Cancer Res. 8, 1139-1146 (2002).
24. Sun, B., Halmos, G., Schally, A. V., Wang, X. & Martinez, M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate 42, 295-303 (2000).
25. Markwalder, R. & Reubi, J. C. Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation. Cancer Res. 59, 1152-1159 (1999).
26. Weber, H. C. Regulation and signaling of human bombesin receptors and their biological effects. Curr. Opin. Endocrinol. Diabetes Obes. 16, 66-71 (2009).
27. Bartholdi, M. F. et al. In situ hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma. Int. J. Cancer 79, 82-90 (1998).
28. Ananias, H. J., van den Heuvel, M. C., Helfrich, W. & de Jong, I. J. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 69, 1101-1108 (2009).
29. Beer, M. et al. Profiling gastrin-releasing peptide receptor in prostate tissues: Clinical implications and molecular correlates. Prostate 72, 318-325 (2012).
30. Swanson, G. P., Thompson, I. M. & Basler, J. Current status of lymph node-positive prostate cancer: Incidence and predictors of outcome. Cancer 107, 439-450 (2006).
31. Giannarini, G., Petralia, G. & Thoeny, H. C. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: A critical analysis of the literature. Eur. Urol. 61, 326-340 (2012).
32. Gornik, G. et al. Evaluation of the GRPR radioantagonist Cu 64 CB TE2A AR 06 in mice and men [abstract]. J. Nucl. Med. 52 (Suppl. 1), 7P (2011).
33. Scopinaro, F. et al. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur. J. Nucl. Med. Mol. Imaging 30, 1378-1382 (2003).
34. de Visser, M. et al. Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts. J. Nucl. Med. 48, 88-93 (2007).
35. Schroeder, R. P. et al. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts. Int. J. Cancer 126, 2826-2834 (2010).
36. Gugger, M. & Reubi, J. C. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am. J. Pathol. 155, 2067-2076 (1999).
37. Fleischmann, A., Waser, B. & Reubi, J. C. Overexpression of gastrin-releasing peptide receptors in tumor-associated blood vessels of human ovarian neoplasms. Cell Oncol. 29, 421-433 (2007).
38. Bjenning, C., Farrell, A. P. & Holmgren, S. Bombesin-like immunoreactivity in skates and the in vitro effect of bombesin on coronary vessels from the longnose skate, Raja rhina. Regul. Pept. 35, 207-219 (1991).
39. Clive, S., Jodrell, D. & Webb, D. Gastrin-releasing peptide is a potent vasodilator in humans. Clin. Pharmacol. Ther. 69, 252-259 (2001).
40. Heuser, M. et al. Expression of gastrin releasing peptide receptor in renal cell carcinomas: A potential function for the regulation of neoangiogenesis and microvascular perfusion. J. Urol. 173, 2154-2159 (2005).
41. Luu, T. N. et al. Different responses of the human gastroepiploic and internal mammary arteries to vasoactive peptides. Am. J. Physiol. 264, H583- H587 (1993).
42. Bunnett, N. in Gut Peptides: Comprehensive Endocrinology (eds Walsh, J. H. & Dockray, G. J.) 423-445 (Raven Press Ltd, New York, 1994).
43. Jensen, J. A., Carroll, R. E. & Benya, R. V. The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 22, 689-699 (2001).
44. Kim, J. S., McKinnis, V. S. & White, S. R. Migration of guinea pig airway epithelial cells in response to bombesin analogues. Am. J. Respir. Cell. Mol. Biol. 16, 259-266 (1997).
45. Yule, K. A. & White, S. R. Migration of 3T3 and lung fibroblasts in response to calcitonin gene-related peptide and bombesin. Exp. Lung Res. 25, 261-273 (1999).
46. Bajo, A. M., Schally, A. V., Groot, K. & Szepeshazi, K. Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers. Br. J. Cancer 90, 245-252 (2004).
47. Levine, L., Licci, J. A. 3rd, Townsend, C. M. Jr & Hellmich, M. R. Expression of gastrin-releasing peptide receptors in endometrial cancer. J. Am. Coll. Surg. 196, 898-904 (2003).
48. Levine, L. et al. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res. 63, 3495-3502 (2003).
49. Reubi, J. C., Fleischmann, A., Waser, B. & Rehmann, R. Concomitant vascular GRP-receptor and VEGF-receptor expression in human tumors: Molecular basis for dual targeting of tumoral vasculature. Peptides 32, 1457-1462 (2011).
50. Chevalier, S. et al. Vascular endothelial growth factor and signaling in the prostate: More than angiogenesis. Mol. Cell. Endocrinol. 189, 169-179 (2002).
51. Narazaki, M. & Tosato, G. Targeting coagulation to the tumor microvasculature: Perspectives and therapeutic implications from preclinical studies. J. Natl Cancer Inst. 97, 705-707 (2005).
52. Stenzl, A. et al. Treatment of muscle-invasive and metastatic bladder cancer: Update of the EAU guidelines. Eur. Urol. 59, 1009-1018 (2011).
53. Moody, T. W. et al. GRP receptors are present in non small cell lung cancer cells. J. Cell. Biochem. Suppl. 24, 247-256 (1996).
54. Carroll, R. E., Ostrovskiy, D., Lee, S., Danilkovich, A. & Benya, R. V. Characterization of gastrin-releasing peptide and its receptor aberrantly expressed by human colon cancer cell lines. Mol. Pharmacol. 58, 601-607 (2000).
55. Fleischmann, A., Waser, B., Gebbers, J. O. & Reubi, J. C. Gastrin-releasing peptide receptors in normal and neoplastic human uterus: Involvement of multiple tissue compartments. J. Clin. Endocrinol. Metab. 90, 4722-4729 (2005).
56. Moody, T. W., Carney, D. N., Cuttitta, F., Quattrocchi, K. & Minna, J. D. High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancer. Life Sci. 37, 105-113 (1985).
57. Pansky, A. et al. Gastrin releasing peptide-preferring bombesin receptors mediate growth of human renal cell carcinoma. J. Am. Soc. Nephrol. 11, 1409-1418 (2000).
58. Reubi, J. C., Korner, M., Waser, B., Mazzucchelli, L. & Guillou, L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur. J. Nucl. Med. Mol. Imaging 31, 803-810 (2004).
59. Fleischmann, A., Laderach, U., Friess, H., Buechler, M. W. & Reubi, J. C. Bombesin receptors in distinct tissue compartments of human pancreatic diseases. Lab. Invest. 80, 1807-1817 (2000).
60. Hohla, F. & Schally, A. V. Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer. Cell Cycle 9, 1738-1741 (2010).
61. Schally, A. V. et al. Hypothalamic hormones and cancer. Front. Neuroendocrinol. 22, 248-291 (2001).
62. Schally, A. V., Comaru-Schally, A. M. & Redding, T. W. Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc. Soc. Exp. Biol. Med. 175, 259-281 (1984).
63. Bajo, A. M. et al. Bombesin antagonists inhibit growth of MDA MB 435 estrogen-independent breast cancers and decrease the expression of the ErbB 2/HER 2 oncoprotein and c jun and c fos oncogenes. Proc. Natl Acad. Sci. USA 99, 3836-3841 (2002).
64. Coy, D. H. et al. Probing peptide backbone function in bombesin. A reduced peptide bond analogue with potent and specific receptor antagonist activity. J. Biol. Chem. 263, 5056-5060 (1988).
65. Schwartsmann, G. et al. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest. New Drugs 24, 403-412 (2006).
66. Shokeen, M. & Anderson, C. J. Molecular imaging of cancer with copper 64 radiopharmaceuticals and positron emission tomography (PET). Acc. Chem. Res. 42, 832-841 (2009).
67. Wild, D. et al. Alpha-versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi DOTA PESIN and 213Bi-AMBA versus 177Lu DOTA PESIN). Cancer Res. 71, 1009-1018 (2011).
68. Morgenstern, A. et al. Synthesis of 213Bi-DOTATOC for peptide receptor alpha-therapy of GEP-NET patients refractory to beta therapy. J. Nucl. Med. 53, 455 (2012).
69. Maecke, H. R. & Reubi, J. C. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J. Nucl. Med. 52, 841-844 (2011).
70. Baidoo, K. E. et al. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjug. Chem. 9, 218-225 (1998).
71. Lin, K. S. et al. A new high affinity technetium 99m bombesin analogue with low abdominal accumulation. Bioconjug. Chem. 16, 43-50 (2005).
72. Nock, B. et al. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur. J. Nucl. Med. Mol. Imaging 30, 247-258 (2003).
73. Van de Wiele, C. et al. Technetium 99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: A feasibility study. Eur. J. Nucl. Med. 27, 1694-1699 (2000).
74. Van de Wiele, C. et al. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J. Nucl. Med. 49, 260-264 (2008).
75. Van de Wiele, C. et al. Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J. Nucl. Med. 42, 1722-1727 (2001).
76. De Vincentis, G. et al. Role of 99mTc-bombesin scan in diagnosis and staging of prostate cancer. Cancer Biother. Radiopharm. 19, 81-84 (2004).
77. Dijkgraaf, I. et al. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog. J. Nucl. Med. 53, 947-952 (2012).
78. Zhang, X. et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J. Nucl. Med. 47, 492-501 (2006).
79. Hoffman, T. J. & Smith, C. J. True radiotracers: Cu 64 targeting vectors based upon bombesin peptide. Nucl. Med. Biol. 36, 579-585 (2009).
80. Chen, X. et al. microPET and autoradiographic imaging of GRP receptor expression with 64Cu DOTA [Lys3]bombesin in human prostate adenocarcinoma xenografts. J. Nucl. Med. 45, 1390-1397 (2004).
81. Garrison, J. C. et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: Side by side comparison of the CB TE2A and DOTA chelation systems. J. Nucl. Med. 48, 1327-1337 (2007).
82. Lears, K. A. et al. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J. Nucl. Med. 52, 470-477 (2011).
83. Zhang, H. et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium 111, lutetium 177, and yttrium 90 for targeting bombesin receptor-expressing tumors. Cancer Res. 64, 6707-6715 (2004).
84. Dimitrakopoulou-Strauss, A. et al. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: Comparison with 18F-FDG. J. Nucl. Med. 48, 1245-1250 (2007).
85. Lantry, L. E. et al. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP R agonist for systemic radiotherapy of prostate cancer. J. Nucl. Med. 47, 1144-1152 (2006).
86. Waser, B., Eltschinger, V., Linder, K., Nunn, A. & Reubi, J. C. Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177Lu-AMBA. Eur. J. Nucl. Med. Mol. Imaging 34, 95-100 (2007).
87. Maddalena, M. E. et al. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP R expression. J. Nucl. Med. 50, 2017-2024 (2009).
88. Bodei, L. et al. 177Lu-AMBA Bombesin analogue in hormone refractory prostate cancer patients: A phase I escalation study with single-cycle administrations. Eur. J. Nucl. Med. Mol. Imaging 34, S221 (2007).
89. Ginj, M. et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc. Natl Acad. Sci. USA 103, 16436-16441 (2006).
90. Cescato, R. et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J. Nucl. Med. 49, 318-326 (2008).
91. Mansi, R et al. Evaluation of a 1,4,7,10 tetraazacyclododecane 1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin. Cancer Res. 15, 5240-5249 (2009).
92. Mansi, R. et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur. J. Nucl. Med. Mol. Imaging 38, 97-107 (2011).
93. Minn, H. et al. Detection of prostate cancer using 68Ga-labelled bombesin analogue BAY 86-7548 in patients undergoing radical prostatectomy [abstract OP507]. Eur. J. Nucl. Med. Mol. Imaging 39, S155- S303 (2012).
94. Abiraj, K. et al. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J. Nucl. Med. 52, 1970-1978 (2011).
95. Mu, L. et al. In vitro and in vivo characterization of novel 18F-labeled bombesin analogues for targeting GRPR-positive tumors. Bioconjug. Chem. 21, 1864-1871 (2010).
96. Honer, M. et al. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. J. Nucl. Med. 52, 270-278 (2011).
97. Li, Z. B., Wu, Z., Chen, K., Ryu, E. K. & Chen, X. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J. Nucl. Med. 49, 453-461 (2008).
98. Schally, A. V., Engel, J. B., Emons, G., Block, N. L. & Pinski, J. Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. Curr. Drug Deliv. 8, 11-25 (2011).
99. Kiaris, H. et al. Targeted cytotoxic analogue of bombesin/gastrin- releasing peptide inhibits the growth of H 69 human small-cell lung carcinoma in nude mice. Br. J. Cancer 81, 966-971 (1999).
100. Stangelberger, A. et al. Targeted chemotherapy with cytotoxic bombesin analogue AN 215 inhibits growth of experimental human prostate cancers. Int. J. Cancer 118, 222-229 (2006).
101. Safavy, A., Raisch, K. P., Khazaeli, M. B., Buchsbaum, D. J. & Bonner, J. A. Paclitaxel derivatives for targeted therapy of cancer: Toward the development of smart taxanes. J. Med. Chem. 42, 4919-4924 (1999).
102. Engel, J. B., Schally, A. V., Dietl, J., Rieger, L. & Honig, A. Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol. Pharm. 4, 652-658 (2007).
103. Moody, T. W. et al. Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells. J. Biol. Chem. 279, 23580-23589 (2004).
104. Moody, T. W. et al. In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors. J. Pharmacol. Exp. Ther. 318, 1265-1272 (2006).
105. Engel, J. B. et al. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN 215. Clin. Cancer Res. 11, 2408-2415 (2005).